CA3144113A1 - Method for treating idiopathic pulmonary fibrosis - Google Patents
Method for treating idiopathic pulmonary fibrosis Download PDFInfo
- Publication number
- CA3144113A1 CA3144113A1 CA3144113A CA3144113A CA3144113A1 CA 3144113 A1 CA3144113 A1 CA 3144113A1 CA 3144113 A CA3144113 A CA 3144113A CA 3144113 A CA3144113 A CA 3144113A CA 3144113 A1 CA3144113 A1 CA 3144113A1
- Authority
- CA
- Canada
- Prior art keywords
- days
- compound
- group
- administered
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/04—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019092675 | 2019-06-25 | ||
| CNPCT/CN2019/092675 | 2019-06-25 | ||
| PCT/CN2020/097881 WO2020259528A1 (zh) | 2019-06-25 | 2020-06-24 | 治疗特发性肺纤维化的方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3144113A1 true CA3144113A1 (en) | 2020-12-30 |
Family
ID=74061495
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3144113A Pending CA3144113A1 (en) | 2019-06-25 | 2020-06-24 | Method for treating idiopathic pulmonary fibrosis |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12582653B2 (https=) |
| EP (1) | EP3992183A4 (https=) |
| JP (1) | JP7615061B2 (https=) |
| KR (1) | KR20220029681A (https=) |
| CN (2) | CN114026072A (https=) |
| AU (1) | AU2020305979B2 (https=) |
| BR (1) | BR112021026214A2 (https=) |
| CA (1) | CA3144113A1 (https=) |
| IL (1) | IL289192A (https=) |
| TW (1) | TWI804743B (https=) |
| WO (1) | WO2020259528A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023539276A (ja) * | 2020-08-31 | 2023-09-13 | ベイジン タイド ファーマシューティカル カンパニー リミテッド | Ｒｈｏ関連タンパク質キナーゼ阻害剤の塩、その固体形態、その調製方法およびその使用 |
| CA3209240A1 (en) * | 2021-02-22 | 2022-08-25 | Samuel D. Waksal | Rock2 inhibitor for the treatment of viral infection |
| NO346587B1 (en) * | 2021-06-02 | 2022-10-17 | Axichem Ab | Capsaicin derivatives in the treatment of idiopathic pulmonary fibrosis |
| TW202327608A (zh) * | 2021-09-17 | 2023-07-16 | 北京泰德製藥股份有限公司 | 治療病毒感染的方法 |
| IL311447A (en) * | 2021-09-18 | 2024-05-01 | Beijing Tide Pharmaceutical Co Ltd | A solid form of a Rho-linked protein kinase inhibitor or a solvate thereof, a method of preparation and use thereof |
| KR20240095429A (ko) * | 2021-11-16 | 2024-06-25 | 베이징 타이드 파마슈티컬 코퍼레이션 리미티드 | Rock2 억제제의 나노결정 제제 및 이의 제조방법 |
| WO2023134688A1 (zh) * | 2022-01-13 | 2023-07-20 | 武汉朗来科技发展有限公司 | 一种rock抑制剂的盐及盐的晶型、组合物和药物用途 |
| EP4591863A1 (en) * | 2022-10-13 | 2025-07-30 | Beijing Tide Pharmaceutical Co., Ltd. | Method for treating pneumoconiosis |
| WO2025017499A1 (en) | 2023-07-17 | 2025-01-23 | Graviton Bioscience Bv | Formulations and uses of rock2 inhibitors for als |
| IL325831A (en) | 2023-07-17 | 2026-03-01 | Graviton Bioscience Bv | ROCK2 inhibitor formulations for central nervous system disorders |
| WO2025069008A1 (en) | 2023-09-28 | 2025-04-03 | Graviton Bioscience Bv | Therapy for treating type 1 diabetes using rock2 and dyrk1 inhibitors |
| WO2025069009A1 (en) | 2023-09-29 | 2025-04-03 | Graviton Bioscience Bv | Rock2 inhibitors in the treatment of obesity |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016138335A1 (en) * | 2015-02-27 | 2016-09-01 | Lycera Corporation | Indazolyl thiadiazolamines and related compounds for inhibition of rho-associated protein kinase and the treatment of disease |
| AR110401A1 (es) | 2016-12-21 | 2019-03-27 | Chiesi Farm Spa | Derivados dihidropirimidina bicíclica-carboxamida como inhibidores de rho-quinasa |
| CN110582489B (zh) * | 2017-06-30 | 2023-10-27 | 北京泰德制药股份有限公司 | Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途 |
| WO2019000682A1 (zh) * | 2017-06-30 | 2019-01-03 | 北京泰德制药股份有限公司 | Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途 |
-
2020
- 2020-06-24 CA CA3144113A patent/CA3144113A1/en active Pending
- 2020-06-24 TW TW109121568A patent/TWI804743B/zh active
- 2020-06-24 BR BR112021026214A patent/BR112021026214A2/pt unknown
- 2020-06-24 CN CN202080045478.XA patent/CN114026072A/zh active Pending
- 2020-06-24 JP JP2021576479A patent/JP7615061B2/ja active Active
- 2020-06-24 US US17/621,719 patent/US12582653B2/en active Active
- 2020-06-24 WO PCT/CN2020/097881 patent/WO2020259528A1/zh not_active Ceased
- 2020-06-24 CN CN202510159677.8A patent/CN119868365A/zh active Pending
- 2020-06-24 EP EP20833444.1A patent/EP3992183A4/en active Pending
- 2020-06-24 AU AU2020305979A patent/AU2020305979B2/en active Active
- 2020-06-24 KR KR1020227002368A patent/KR20220029681A/ko active Pending
-
2021
- 2021-12-21 IL IL289192A patent/IL289192A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3992183A1 (en) | 2022-05-04 |
| US20220233538A1 (en) | 2022-07-28 |
| EP3992183A4 (en) | 2023-06-21 |
| TW202114679A (zh) | 2021-04-16 |
| KR20220029681A (ko) | 2022-03-08 |
| US12582653B2 (en) | 2026-03-24 |
| AU2020305979A1 (en) | 2022-02-17 |
| IL289192A (en) | 2022-02-01 |
| JP2022539329A (ja) | 2022-09-08 |
| JP7615061B2 (ja) | 2025-01-16 |
| CN114026072A (zh) | 2022-02-08 |
| AU2020305979B2 (en) | 2026-04-23 |
| WO2020259528A1 (zh) | 2020-12-30 |
| CN119868365A (zh) | 2025-04-25 |
| TWI804743B (zh) | 2023-06-11 |
| BR112021026214A2 (pt) | 2022-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12582653B2 (en) | Method for treating idiopathic pulmonary fibrosis | |
| US11292799B2 (en) | Substituted azetidine dihydrothienopyrimidines and their use as phosphodiesterase inhibitors | |
| IL285989B1 (en) | Method for treating fatty liver disease and/or steatohepatitis | |
| US11981681B2 (en) | Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitors | |
| JP2018138609A (ja) | ナフチリジンジオン誘導体 | |
| US20190202827A1 (en) | Fluorine-containing triazolopyridine, and manufacturing method, pharmaceutical composition, and application thereof | |
| JP2020500920A (ja) | 置換ピラゾロアゼピン−４−オンおよびそれらのホスホジエステラーゼ阻害剤としての使用 | |
| EP4501918A1 (en) | 3-phenylisoxazole derivative, and pharmaceutical composition for preventing or treating eye disease, containing same as active ingredient | |
| JP7803924B2 (ja) | 造血幹細胞移植によって引き起こされる移植片対宿主病を治療する方法 | |
| SG11202111877TA (en) | Method for treating cough by using diaminopyrimidine compound | |
| WO2022010951A1 (en) | Antiviral use of fabp4 modulating compounds | |
| HK40064686A (en) | Method for treating idiopathic pulmonary fibrosis | |
| HK40063173A (en) | Method for treating idiopathic pulmonary fibrosis | |
| US12138243B2 (en) | Antiviral use of FABP4 modulating compounds | |
| EP4591863A1 (en) | Method for treating pneumoconiosis | |
| CN114685472B (zh) | 多取代的尿嘧啶衍生物及其用途 | |
| HK40121343A (zh) | 治疗特发性肺纤维化的方法 | |
| HK40086216A (en) | Method for treating graft versus host disease caused by hematopoietic stem cell transplantation | |
| JP2025529076A (ja) | ＡｈＲ媒介疾患の治療に使用するタピナロおよびそのアナログ製剤 | |
| HK40058942A (en) | Method for treating fatty liver disease and/or steatohepatitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220805 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20240808 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20241203 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250205 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250513 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250514 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250606 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250606 |